-
1 Comment
Shenzhen Hepalink Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 16.2% below its 200 day moving average.
From a valuation standpoint, the stock is 54.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd's total revenue rose by 20.5% to $2B since the same quarter in the previous year.
Its net income has dropped by 18.7% to $316M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.2% to $-45M since the same quarter in the previous year.
Based on the above factors, Shenzhen Hepalink Pharmaceutical Group Co., Ltd gets an overall score of 3/5.
| ISIN | CNE100000P02 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| Beta | 0.46 |
|---|---|
| Target Price | 7.4 |
| Market Cap | 14B |
| PE Ratio | 24.68 |
| Dividend Yield | None |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in research, development, production, services, and trading biopharmaceutical; property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002399.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
